# Antiepileptic drugs in glioblastoma survival: dichotomic or treatment and mechanism of action-dependent variable?

**Authors:** Oktay Genel, Sultan Alzarouni, Asfand Baig Mirza, Prajwal Ghimire, Sarah Murden, Yasir A Chowdhury, Ali Elhag, Katia Cikurel, Dorothy Joe, Gerald Finnerty, Vishal Manik, Angela Swampillai, Omar Al-Salihi, Kazumi Chia, Lucy Brazil, Samantha Forner, Jennifer Glendenning, Richard Gullan, Keyoumars Ashkan, Ranjeev Bhangoo, Francesco Vergani, José Pedro Lavrador

PMC · DOI: 10.1093/noajnl/vdag035 · Neuro-Oncology Advances · 2026-02-11

## TL;DR

This study examines how antiepileptic drugs affect survival in glioblastoma patients, finding no overall impact but some trends with specific drug types.

## Contribution

The study explores the relationship between antiepileptic drug mechanisms and glioblastoma survival, revealing potential interactions with adjuvant treatments.

## Key findings

- Overall, AED use did not significantly affect glioblastoma patient survival.
- Voltage-gated sodium channel blockers showed a trend toward improved survival at 24 months.
- AED use appeared to influence the effectiveness of adjuvant treatments.

## Abstract

Recent evidence has demonstrated a tight relationship between neuronal activity and glioblastoma (GBM) growth, involving novel mechanisms such as neuron-glioma synapses and tumor microtube networks. Seizure activity and antiepileptic drug (AED) usage are highly prevalent among GBM patients. In this study, we investigate the impact of AEDs and their mechanism of action on overall survival (OS) in a cohort of patients treated for GBM.

We performed a retrospective, single-center study of a cohort of histopathologically proven GBM patients at a tertiary center. Multivariate analyses were performed at 4 different timepoints by (1) patients who did and did not use AEDs, (2) use of individual AEDs, and (3) use of AEDs with the same mechanism of action.

A total of 236 patients were included in the analysis, 178 of which were on anti-epileptics (75.4%). There was no significant impact of AEDs overall in OS—median survival was 16.2 months for patients taking AEDs and 13.8 months for patients not. Being on a voltage-gated sodium channel (VGNC) blocker seemed to confer a significant survival advantage at 24 months when compared with patients not on AEDs (hazard ratio [HR] = 0.67, P = .045). This significance was, however, lost when corrected for covariates (multivariable HR = 1.01, confidence interval [CI] = 0.67-1.54, P = .953). While patients on adjuvant treatment had a higher OS, this was only the case in patients ­taking AEDs.

There was no significant effect of AEDs on OS, VGNC blockers trended toward significance at 24 months. However, a link may exist between AEDs and the impact of adjuvant treatments.

## Linked entities

- **Diseases:** glioblastoma (MONDO:0018177)

## Full-text entities

- **Diseases:** Seizure (MESH:D012640), epileptics (MESH:D004827), GBM (MESH:D005909), tumor (MESH:D009369), glioma (MESH:D005910)
- **Chemicals:** VGNC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990308/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990308/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990308/full.md

---
Source: https://tomesphere.com/paper/PMC12990308